Deleting the Target: Eliminating Androgen Receptors

 

Clinical Trials & Emerging Therapies

A New “AR-Degrader” Trial Opens for Advanced Prostate Cancer

GSK has begun the first human study of GSK5471713, an experimental drug designed not just to block the androgen receptor but to destroy it. Here is what the trial does, why it asks for the patients it asks for, and how a man might think through whether joining makes sense.

for the IPCSG Newsletter  |  Reviewed September 2026

Bottom Line Up Front

A new Phase 1/2 clinical trial (identifier NCT07332455) is now recruiting men with metastatic castration-resistant prostate cancer (mCRPC) to test GSK5471713, an experimental GSK drug that belongs to the emerging class of androgen-receptor (AR) degraders. Instead of merely blocking the receptor the way enzalutamide or abiraterone do, degraders aim to tag the AR protein for the cell’s own disposal system so it is broken down entirely.

This is an early, first-in-human study. Its main job is to find a safe dose and watch for side effects; it is not yet designed to prove the drug works. Roughly 54 participants will be enrolled across about a dozen sites in the U.S., Canada, Australia, Japan, and South Korea, with San Diego’s UC San Diego among the U.S. investigator sites.

Why it matters: the androgen receptor is the engine that keeps driving prostate cancer even after standard hormone therapies fail. If degraders can remove that engine rather than just jam it, they may sidestep some of the resistance tricks that let tumors keep growing. GSK5471713 joins a well-funded field led by drugs like luxdegalutamide (ARV-766) and bavdegalutamide (ARV-110).

Blocking a receptor versus removing it

Almost every prostate-cancer therapy targets the same weak point: the androgen receptor. Think of the AR as a switch inside the cancer cell. When male hormones (androgens) flip it on, the cell is told to grow and divide. Hormone therapies work by starving the switch of fuel (abiraterone lowers androgen production) or by taping over the switch so hormones cannot reach it (enzalutamide, apalutamide, and darolutamide are receptor blockers).

The trouble is that the switch itself is still there. Over time the tumor learns to work around a taped-over switch. It can build more switches (AR overexpression), change the shape of the keyhole so the tape no longer fits (mutations in the receptor’s ligand-binding domain), manufacture stripped-down switches that are permanently stuck “on” (splice variants such as AR-V7), or brew its own fuel inside the tumor. These are the classic routes to castration resistance, and they are why a man can respond beautifully to hormone therapy for a while and then progress.

An AR degrader takes a different tack. Rather than covering the switch, it recruits the cell’s built-in recycling machinery — the ubiquitin–proteasome system — to shred the switch and haul it away. For an engineer, the distinction is the difference between disconnecting a faulty relay and unsoldering it from the board. If the receptor protein is physically gone, several of the resistance work-arounds that depend on having a receptor to exploit lose their footing. That is the central hypothesis the whole degrader field is testing.

A note on what GSK has and hasn’t said

GSK has not published the full molecular details of GSK5471713. Two things point clearly to it being an AR degrader: the trial explicitly excludes men who have already received “AR degrader targeted therapy,” and GSK has been actively building a targeted-protein-degradation program. So while the exact sub-type of degrader (for example, a PROTAC versus a molecular glue) has not been disclosed, the AR-degrader classification is well supported. We will update readers as GSK releases more.

The trial at a glance

The study’s formal title is “A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Dose Optimization Study of GSK5471713 in Adult Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC).” In plain terms: everyone in the study gets the drug (there is no placebo group), doctors and patients both know the dose, and the dose is raised step by step in successive groups to map out the safe range.

Key facts

Trial ID

NCT07332455 (EU CT 2025-523874-17; GSK study 300164)

Sponsor

GSK (GlaxoSmithKline)

Drug

GSK5471713, given by itself (monotherapy)

Phase

1/2, first-in-human, open-label

Target enrollment

About 54 participants

Status

Recruiting (as of the July 2026 record update)

Started

February 2026

Est. primary completion

March 2028

Est. study completion

March 2030

Locations

~11 sites across the U.S., Canada, Australia, Japan, and South Korea

Who the study is looking for

The eligibility rules describe men whose disease has already traveled the standard treatment road. In broad strokes, a participant needs to have:

• mCRPC with a confirmed adenocarcinoma of the prostate (the common type), that has progressed despite androgen-deprivation therapy (ADT).
• Prior treatment with at least one androgen-receptor pathway inhibitor (such as abiraterone, enzalutamide, apalutamide, or darolutamide).
• One or two prior taxane chemotherapy regimens (docetaxel and/or cabazitaxel).
• A good general performance status (ECOG 0 or 1 — up and about, able to carry out light activity).

The study screens out men whose tumors have turned into small-cell or neuroendocrine cancer (a biologically different disease), men with significant heart problems or other serious uncontrolled conditions, and — importantly — anyone who has already had an AR-degrader drug. Additional protocol-specific criteria also apply, so eligibility is always confirmed case by case at the trial site.

What the researchers are measuring

Because this is a dose-finding study, the headline measurements are about safety. The team tracks dose-limiting toxicities in the first 28 days of treatment and catalogs all adverse events and serious adverse events, including any that force a dose change. They also measure pharmacokinetics — how much drug reaches the bloodstream (peak concentration and total exposure) and how quickly. Alongside those, the study collects two early signals of activity that patients will recognize: the share of men whose PSA falls by at least 50% (a “PSA50” response, confirmed at least three weeks later) and the objective response rate — measurable tumor shrinkage judged by imaging using Prostate Cancer Working Group 3 (PCWG3) criteria.

A local connection

Among the trial’s listed investigators is Dr. Rana McKay, a genitourinary oncologist at UC San Diego. Dr. McKay is a familiar name in prostate-cancer research and, at the 2026 ASCO Genitourinary Cancers Symposium, presented a separate trial of the AR-degrader luxdegalutamide combined with abiraterone. For San Diego patients, having an active investigator nearby is worth knowing when discussing options with your own care team.

Why the study asks for prior taxane treatment

Several readers have raised a sharp question: if taxane chemotherapy has such modest results, why do so many trials require it before you can enroll? It is a fair challenge, and the answer says more about how trials are positioned than about how much good the chemo did.

The core reason is ethics and sequencing. A first-in-human drug is, by definition, an unknown quantity — nobody yet knows whether it is safe or effective. It would not be right to offer an untested molecule to a man who still has proven, life-extending standard options in front of him. So early trials deliberately enroll the most heavily pretreated patients — men who have already moved through ADT, an ARPI, and one or two taxanes — because for them the standard toolkit is largely spent, and the risk-and-benefit math of trying something experimental genuinely changes. A few related reasons follow from that same logic:

• A clean, comparable population. “Progressed on ADT plus an ARPI plus one to two taxanes” describes a specific disease state that looks the same at every site, so results can actually be interpreted and compared.
• Where approval is earned first. The post-taxane, post-ARPI setting is a real unmet need with few remaining options, which is where regulators are most receptive to a new drug. Agents that succeed there are routinely moved earlier in the disease later on — the field even has a nickname for it, “line creep.”
• It reflects the current standard sequence. Taxanes are guideline-standard in advanced prostate cancer, so “prior taxane” is really shorthand for “has already been through standard care.”

Do taxanes actually work?

Here the nuance matters. In the castration-resistant setting, the skeptics have a point: docetaxel’s landmark trial (TAX327) showed a median overall-survival gain of only about two to three months over the older comparator (roughly 19 months versus 16.5), and cabazitaxel after docetaxel is similarly modest — real, but measured in weeks to months, and with genuine toxicity. That is very likely the picture many patients have in mind.

But the same drug looks very different earlier in the disease. When docetaxel is added to ADT up front in metastatic hormone-sensitive disease, the CHAARTED trial found a median survival benefit of about 13 months, and the STAMPEDE trial found roughly 10 months — with the largest gains in men who had high-volume disease. Same molecule, dramatically different payoff depending on when it is used. So “taxanes don’t work” is too broad; “taxanes add only modestly once the cancer is castration-resistant” is closer to the truth.

The reassuring part

The prior-taxane requirement is about a man’s history, not his future in the study. For someone enrolling now, the chemotherapy and its side effects are largely behind him. Joining this trial does not mean more taxane — it means facing the side-effect profile of GSK5471713 instead. That is a meaningful distinction, and it leads straight into the question every man should be asking.

Should you consider a Phase 1 trial like this one?

The side effects of both chemotherapy and experimental drugs are a legitimate worry, and this trial is not the right choice for every man. But the decision becomes clearer when the comparison is framed honestly. It is usually not “experimental drug versus a safe standard treatment.” For the man this trial recruits — already past ADT, an ARPI, and one or two taxanes — the realistic alternatives are limited: a few later-line options if he qualifies, or best supportive care. Weighed against that, an unproven but mechanistically promising drug looks different than it would for a man with good options still in hand.

It also helps to know that the forward-looking risk here is the degrader, not more chemo. As a class, AR degraders have generally shown more targeted and more manageable side effects than taxanes — though “first-in-human” means this particular drug’s profile is exactly what the study is still working out, so real unknowns remain. With that framing, here is the honest ledger.

The case for

• Early access. If the drug works, a responder receives it years before it could reach the market. Related degraders have already produced real PSA responses in some heavily pretreated men.
• Intensive oversight. Trial patients get frequent imaging, labs, and specialist attention that often exceeds routine care.
• No placebo. This study is open-label — everyone receives the drug. The old fear of “getting the sugar pill” does not apply here.
• Contribution. Many men join partly to advance the science and help those who come after them. That motive is legitimate and worth honoring.

The case against

• Phase 1’s job is safety, not benefit. Response is unpredictable at this stage, and early groups may receive low doses being tested precisely because they might be too weak to help.
• Genuine unknowns. First-in-human means some side effects are not yet characterized.
• Burden and opportunity cost. Frequent visits, biopsies, blood draws, and travel carry a quality-of-life price — and enrolling can close the door on other trials or treatments.

Questions to bring to your care team

• Given my prior treatments and current disease, what are my realistic options right now — including trials other than this one?
• What side effects have been seen so far with this drug or others like it, and how would we watch for and manage them?
• What would participation actually demand of me — visit frequency, biopsies, travel — and how would that affect my daily life?
• If I join, could it make me ineligible for a treatment or trial I might want later?
• What are the signs we would use to decide the drug is (or is not) helping me, and how quickly would we know?
• How do my own priorities — length of life versus quality of life, time at home, comfort — line up with what this study asks?

Where this lands is genuinely individual. It turns on how much disease a man has, what he has already tried, what else is realistically open to him, and how he weighs added time against quality of life. For some, the monitoring and the shot at something new outweigh the burden; for others, protecting good time at home is the wiser choice. There is no universally correct answer — which is exactly why the real work happens in a specific, unhurried conversation with your own oncologist.

Where GSK5471713 fits in a crowded field

GSK5471713 is not arriving in an empty room. AR degraders have become one of the most closely watched frontiers in prostate cancer, and several are further along:

• Bavdegalutamide (ARV-110) — the first-generation PROTAC AR degrader from Arvinas, which produced the early clinical proof that degrading the AR in men could be done.
• Luxdegalutamide (ARV-766, also called JSB462) — Arvinas’s second-generation degrader, engineered to break down not only normal AR but also the mutated forms (such as L702H, H875Y, and T878A) that fuel resistance. In reported Phase 1/2 data, about 43% of evaluable men with these AR mutations had a PSA drop of at least 50%, with a manageable safety profile. In 2024, Arvinas out-licensed this drug to Novartis, which is now running Phase 2 combination studies (including with the radioligand therapy Pluvicto and with abiraterone).

Against that backdrop, GSK5471713 is a newcomer at the earliest stage — but a newcomer backed by a major manufacturer that is clearly investing in this biology. GSK also has a second prostate-cancer candidate, GSK5458514, in its own early trial, a sign that the company is building more than a one-off effort here.

The business and legal backdrop

Patients rightly ask whether the money and paperwork behind a drug tell us anything about its prospects. A few concrete, on-the-record items help frame the field:

• A billion-dollar bet on the class. When Novartis licensed luxdegalutamide from Arvinas in 2024, it paid $150 million up front and agreed to up to about $1.01 billion in additional milestone payments plus royalties. Those terms are documented in Arvinas’s public filings with the U.S. Securities and Exchange Commission (its annual 10-K and quarterly 10-Q reports).
• A regulatory clearance, not a courtroom fight. That Arvinas–Novartis deal had to clear the standard U.S. antitrust review under the Hart-Scott-Rodino Act before it could take effect in May 2024 — a routine but real government checkpoint for transactions of this size.
• A first-of-its-kind approval on the horizon. The broader protein-degrader technology is approaching a milestone: vepdegestrant (an estrogen-receptor degrader for breast cancer, from Arvinas and Pfizer) has been moving toward becoming the first approved PROTAC, with commercialization rights later licensed to Rigel Pharmaceuticals in 2026. Prostate-cancer degraders would follow a trail this drug is helping to blaze.
• An intellectual-property gold rush. Legal analysts describe steadily growing patent activity around targeted protein degradation — filings covering specific degrader chemistries, the E3 “disposal” ligases they recruit, and dosing and combination strategies. As of this writing we found no public litigation naming GSK5471713 specifically; the notable legal and regulatory action in this space has centered on licensing deals and patent filings rather than disputes.

The takeaway for patients: heavy investment signals genuine scientific promise, but it does not guarantee that any single early-stage molecule will succeed. Most drugs that enter first-in-human testing do not make it to approval.

---

Sources

1. U.S. National Library of Medicine, ClinicalTrials.gov. “First-Time-in-Human Study of GSK5471713 in Adults With mCRPC” (NCT07332455). https://clinicaltrials.gov/study/NCT07332455
2. GSK Study Register. Trial 300164 — GSK5471713 in mCRPC (status: Recruiting). https://www.gsk-studyregister.com/trials/300164
3. GSK press release, via The Globe and Mail. “GSK Advances New First-in-Human Prostate Cancer Drug Into Early Clinical Testing” (January 13, 2026). theglobeandmail.com
4. UroToday. Clinical trial listing for GSK5471713 Phase 1/2 mCRPC study (March 9, 2026). urotoday.com — GSK5471713 listing
5. Prostate Warriors (patient community). “GSK5471713: An Investigational AR Degrader Targeting Late-Stage Prostate Cancer Resistance” (January 13, 2026). prostatewarriors.com
6. Petrylak DP, et al. “ARV-766, a PROTAC androgen receptor degrader, in mCRPC: Initial results of a Phase 1/2 study.” Journal of Clinical Oncology 42, no. 16_suppl (ASCO 2024): 5011. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.5011
7. Targeted Oncology. “Novel PROTAC AR Degrader Shows Promising Clinical Activity in mCRPC.” targetedonc.com
8. UroToday. “ASCO GU 2026 — TPS275: A Phase II Study of Luxdegalutamide in Combination with Abiraterone in mHSPC” (Dr. Rana McKay; February 27, 2026). urotoday.com — ASCO GU 2026 LuxAR-03
9. Tannock IF, et al. TAX327 study of docetaxel in mCRPC (median overall survival ~18.9 vs 16.5 months). Summarized with CHAARTED and STAMPEDE in: Tucci M, et al. “Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer.” PMC. ncbi.nlm.nih.gov/pmc/articles/PMC4687286
10. CHAARTED and STAMPEDE trials (docetaxel added to ADT in hormone-sensitive disease; ~13-month and ~10-month median survival benefits, respectively). See summary in the STARTAR protocol background. ncbi.nlm.nih.gov/pmc/articles/PMC4687286
11. Arvinas, Inc. Press release. “Arvinas Enters into a Transaction with Novartis … for PROTAC Androgen Receptor Protein Degrader ARV-766” (April 11, 2024). ir.arvinas.com
12. Arvinas, Inc. Form 10-K for fiscal year 2025, U.S. Securities and Exchange Commission (Novartis transaction terms; HSR clearance). sec.gov — Arvinas 10-K FY2025
13. Arvinas, Inc. “Our Science” and “Pipeline” (luxdegalutamide / JSB462; first PROTAC approval; Rigel license, 2026). arvinas.com/our-science
14. Review: “Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer.” PubMed (2024). https://pubmed.ncbi.nlm.nih.gov/38339414/
15. RF EMerge. “Target Acquired, Protein Deleted: The Next Frontier in Precision Medicine and IP Strategy — March 2026 Update” (TPD patent landscape). rfemerge.com
16. ClinicalTrials.gov. “A Study of GSK5458514 … in Participants With Prostate Cancer” (NCT06990880) — GSK’s additional prostate program. https://clinicaltrials.gov/study/NCT06990880

Please note: This article is educational and is not medical advice. Clinical-trial details, recruitment status, and eligibility can change; always verify current information on ClinicalTrials.gov and discuss any trial with your own physician before making treatment decisions. GSK5471713 is investigational and is not approved by any regulatory agency.